SigCure and Genneo Announce Strategic Collaboration to Advance Oncology Drug Discovery with Organoid and Immuno-Oncology Platforms

On September 11, 2024, Signet Therapeutics (hereinafter referred to as "Signet") and Guangzhou Genior Biotech Co., Ltd. (hereinafter referred to as "Genior") officially signed a strategic cooperation agreement.The announcement of the strategic partnership marks a new chapter in which two leading companies in the industry will collaborate in the fields of organoid disease models and tumor immunotherapy drug development, accelerating the innovative progress of organoid-driven breakthrough technologies in new drug research and development.。

As the world's first targeted cancer drug research and development company based on organoid disease models and AI technology,SIGNET, utilizing its exclusive organoid disease model platform, has demonstrated groundbreaking R&D achievements in difficult-to-treat disease areas such as diffuse gastric cancer, ovarian cancer, and triple-negative breast cancer. In just over three years, it has advanced the world's first drug pipeline targeting diffuse gastric cancer and other cancer types to the clinical stage (sigx1094).Through this collaboration, SIGNET will fully utilize its cutting-edge technology in organoid disease models and drug efficacy evaluation platforms, integrating it with Ginneo's profound expertise in tumor immunology CRO services, to build an efficient and precise bridge for target screening, efficacy assessment, and preclinical research of innovative oncology drugs.

Guangzhou Genie BioTech Co., Ltd., an outstanding representative of national high-tech enterprises, focuses on every detail of tumor immunotherapy drug development. It possesses a vast PDX tumor specimen bank, primary cell bank, and diversified disease animal model resources. Its project "Application of PDX Models, Animal Disease Models, and CRC Primary Cells in Anti-tumor New Drug Development" is industry-leading. Through close collaboration with top academic institutions such as Sun Yat-sen University and Guangzhou Chinese Academy of Sciences, Genie BioTech has accumulated extensive experience and achievements in the integration of industry, academia, and research, providing comprehensive and high-quality CRO value-added services for pharmaceutical companies.

The strategic cooperation between Signet Therapeutics and Genie Bio not only represents a powerful combination of the R&D capabilities of both parties but also reflects their pursuit of speed and quality in the development of new cancer drugs.SIGNET and GenieBio Will Join Hands to Explore the Great Potential of Organoid Disease Models and Innovative Cancer Drug Development. Through the Deep Integration of Both Technical Platforms, They Aim to Achieve Rapid Screening and Discovery of Potential Targets and Efficient Transformation of Innovative Targeted Drugs, Allowing Research Results in the Lab to Move Faster and More Steadily Towards Clinical Applications.Bringing more good news to cancer patients。

Ms. Peng Wanfen, Director of the Organoid Model Animal Center at SIGNET, expressed her anticipation for this collaboration, hoping that both parties will work together to address the key technical challenges faced in using organoid disease models to aid new drug development. Through close cooperation, the efficiency and success rate of new drug development will be greatly enhanced, bringing therapeutic hope to patients suffering from cancer who currently have no available treatment options.

Guangzhou Genio BioTech Co., Ltd. stated that SIGNET has demonstrated remarkable achievements in the field of utilizing organoid disease models for new drug development. The company's strong biotechnology R&D capabilities, combined with Genio BioTech's extensive experience in tumor immunotherapy drug development, will provide global pharmaceutical companies with more precise and efficient new drug R&D solutions, accelerating the drug approval process and driving continuous advancements in cancer treatment technology.

This strategic cooperation is an important milestone in the development history of SIGNET's Organoid Model Animal Center and Genie Bio, as well as an innovative integration in the field of cancer drug research and development. In the future, the two companies will move forward hand in hand on the path of biopharmaceutical innovation, jointly creating more R&D cooperation opportunities.

Signet Therapeutics is the first biotech company in China to develop innovative targeted cancer drugs based on organoid disease models and AI. It was initially founded on the Harvard University campus and established its presence in Shenzhen in 2020, completing an angel round of financing worth nearly 150 million RMB within a year. SIGNET is not only a transliteration of Signet but also adheres to the vision of "Hopeful Aspirations, Studying Things to Gain Knowledge." The company leverages organoid disease models that closely resemble the genomic characteristics of patients, playing a key role in drug efficacy evaluation and novel target discovery. By integrating AI-based screening, synthesis, and optimization of small molecule compounds, it develops first-in-class innovative targeted therapies. Currently, the company has three drug pipelines, with the lead pipeline focused on developing the world's first targeted therapy for diffuse gastric cancer, which has now entered clinical trials. Signet Therapeutics operates 1,200 square meters of R&D space and 500 square meters of animal laboratory facilities. Its disease model platform not only supports its internal drug pipelines but also actively empowers large pharmaceutical companies in their new drug development efforts, facilitating the creation of more innovative medicines.